CIC reduces xCT/SLC7A11 expression and glutamate release in glioma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Jong-Whi | - |
dc.contributor.author | Kilic, Omer | - |
dc.contributor.author | Deo, Minh | - |
dc.contributor.author | Jimenez-Cowell, Kevin | - |
dc.contributor.author | Demirdizen, Engin | - |
dc.contributor.author | Kim, Hyunggee | - |
dc.contributor.author | Turcan, Şevin | - |
dc.date.accessioned | 2023-02-21T00:40:04Z | - |
dc.date.available | 2023-02-21T00:40:04Z | - |
dc.date.created | 2023-01-31 | - |
dc.date.issued | 2023-01 | - |
dc.identifier.issn | 2051-5960 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/86909 | - |
dc.description.abstract | Capicua (CIC) is an important downstream molecule of RTK/RAS/MAPK pathway. The regulatory mechanism of CIC underlying tumorigenesis in oligodendroglioma, where CIC is frequently mutated, has yet to be fully elucidated. Using patient-derived glioma lines, RNA-sequencing and bioinformatic analysis of publicly available databases, we investigated how CIC loss- or gain-of-function regulates its downstream targets, cell proliferation and glutamate release. Our results indicate an increased frequency of CIC truncating mutations in oligodendroglioma during progression. In vitro, CIC modulation had a modest effect on cell proliferation in glioma lines, and no significant changes in the expression of <jats:italic>ETV1, ETV4</jats:italic> and <jats:italic>ETV5</jats:italic>. Transcriptional repression of known CIC targets was observed in gliomas expressing non-phosphorylatable CIC variant on Ser173 which was unable to interact with 14-3-3. These data outline a mechanism by which the repressor function of CIC is inhibited by 14-3-3 in gliomas. Using transcriptional profiling, we found that genes related to glutamate release were upregulated because of CIC depletion. In addition, loss of CIC leads to increased extracellular glutamate. Consistent with this, CIC restoration in an oligodendroglioma line reduced the levels of extracellular glutamate, neuronal toxicity and xCT/SLC7A11 expression. Our findings may provide a molecular basis for the prevention of glioma-associated seizures. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BMC | - |
dc.relation.isPartOf | Acta Neuropathologica Communications | - |
dc.title | CIC reduces xCT/SLC7A11 expression and glutamate release in glioma | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000914413300002 | - |
dc.identifier.doi | 10.1186/s40478-023-01507-y | - |
dc.identifier.bibliographicCitation | Acta Neuropathologica Communications, v.11, no.1 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85146333076 | - |
dc.citation.title | Acta Neuropathologica Communications | - |
dc.citation.volume | 11 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Park, Jong-Whi | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Capicua | - |
dc.subject.keywordAuthor | Glutamate | - |
dc.subject.keywordAuthor | Neuronal toxicity | - |
dc.subject.keywordAuthor | Oligodendroglioma | - |
dc.subject.keywordAuthor | xCT/SLC7A11 | - |
dc.subject.keywordPlus | CELL-PROLIFERATION | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | CAPICUA | - |
dc.subject.keywordPlus | TUMORS | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.